Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated September 16, 2025, titled "Dr. Reddy's launches novel molecule Tegoprazan in India".
Press Release Sep 16 2025
Filed with NSE ·
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call6ix hasn’t read this filing yet.
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
- Press Release Jul 23 2025
- Dr. Reddy’s Q1FY26 Financial Results
- Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan
Later from Dr. Reddy's Laboratories
- Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
- Press Release Oct 13 2025
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
- Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
- Press Release Nov 24 2025
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories